The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Advances in myeloma treatment: quadruplets, CAR T-cell therapy and bispecific antibodies
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses advances in the treatment of multiple myeloma. Dr Cerchione highlights the growing role of quadruplet regimens, including findings from PERSEUS (NCT03710603), IMROZ (NCT03319667), and CEPHEUS (NCT03652064), and the potential of sustained measurable residual disease (MRD) negativity to guide treatment discontinuation. He also explores emerging CAR T-cell therapies and bispecific antibodies, and belantamab mafodotin-based combinations following the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
